Patents Assigned to Northeastern Ohio Universities College of Medicine
-
Publication number: 20120039926Abstract: The conjugated peptide constructs described herein can be used to induce production of dendritic cells that generate cytokines. The vaccine-bearing dendritic cells can be administered to induce T cell mediated immune modulating responses.Type: ApplicationFiled: April 14, 2010Publication date: February 16, 2012Applicants: CEL-SCI CORPORATION, NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINEInventors: Kenneth S. Rosenthal, Daniel H. Zimmerman, Patricia R. Taylor
-
Patent number: 7947492Abstract: A device and method is disclosed for improving the detection of a ligand by a receptor by concentrating microbes by removing particulates from fluid-borne samples and/or causing selective aggregation of concentrated microbes. The device may be configured as a multipath valve capable purifying/concentrating a sample in one orientation and delivering the concentrated sample in another orientation. In one embodiment, the device includes a body that defines a plurality of chambers and pathways and supports a pathogen capture unit that houses a receptor that exhibits specificity for a ligand. In another embodiment, the capture unit houses a plurality of antibody coated generally spherical particles capable of binding to a ligand.Type: GrantFiled: August 20, 2008Date of Patent: May 24, 2011Assignee: Northeastern Ohio Universities College of MedicineInventor: Gary D. Niehaus
-
Patent number: 7811811Abstract: The invention relates to self-contained assay cassette for detecting a ligand in a sample. The assay cassette provides for turbulent flow and mixing of the sample with assay components, including receptors that bind to a ligand, optional microspheres capable of binding the receptors or to which other secondary receptors are attached, and liquid crystalline materials. The assay cassette also provides for laminar flow of the mixed sample into a detection chamber where complexes between a receptor, ligand, and optional microspheres, is detected as transmission of polarized light through the detection chambers. The invention also relates to methods for detecting a ligand in a sample using turbulent flow to mix the sample with assay components, including liquid crystalline materials, and laminar flow of the mixed sample such that the liquid crystalline material assumes an ordered conformation in absence of a ligand.Type: GrantFiled: June 7, 2006Date of Patent: October 12, 2010Assignee: Northeastern Ohio Universities College of MedicineInventor: Gary D. Niehaus
-
Publication number: 20100047920Abstract: A device and method is disclosed for improving the detection of a ligand by a receptor by concentrating microbes by removing particulates from fluid-borne samples and/or causing selective aggregation of concentrated microbes. The device may be configured as a multipath valve capable purifying/concentrating a sample in one orientation and delivering the concentrated sample in another orientation. In one embodiment, the device includes a body that defines a plurality of chambers and pathways and supports a pathogen capture unit that houses a receptor that exhibits specificity for a ligand. In another embodiment, the capture unit houses a plurality of antibody coated generally spherical particles capable of binding to a ligand.Type: ApplicationFiled: August 20, 2008Publication date: February 25, 2010Applicant: NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINEInventor: Gary D. Niehaus
-
Publication number: 20090143457Abstract: Described herein are various compounds for treatment of ocular neurodegenerative diseases, including but not limited to glaucoma and diabetic retinopathy. The compounds described herein can act to attenuate and/or block calcium release from external neuronal environments as well as intracellular stores.Type: ApplicationFiled: December 4, 2008Publication date: June 4, 2009Applicant: NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINEInventors: Cornelis J. Van der Schyf, Randolph B. Schiffer, Paula Grammas, Masao Roy Wilson, Werner J. Geldenhuys, Lois-May Bezuidenhout
-
Patent number: 7407815Abstract: A functional cassette for the detection of ligands comprises a first inner housing, a second middle housing and a third outer housing and each housing is at least partially rotatable relative to an adjoining housing. The first inner housing contains a central well adapted for receiving a sample, and the central well is in selectable fluid communication with at least one mixing chambers. The mixing chambers contain a reagent for forming a complex with a ligand. The first inner housing additionally comprises at least one compartments for the storage of a liquid crystalline material, and the compartments are in selectable fluid communication with at least one mixing chambers. The third outer housing comprises at least one detection chambers for observing the light transmission properties of a liquid crystal material and the detection chambers are in selectable fluid communication with the mixing.Type: GrantFiled: September 27, 2006Date of Patent: August 5, 2008Assignees: Kent State University, Northeastern Ohio Universities College of MedicineInventors: Christopher J. Woolverton, Gary D. Niehaus
-
Patent number: 7226904Abstract: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80% identical, preferably at least 90% identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as “ADBP”, one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.Type: GrantFiled: July 27, 2005Date of Patent: June 5, 2007Assignees: Northeastern Ohio Universities College of Medicine, Temple UniversityInventors: Gary B. Schneider, Steven N. Popoff, Fayez Safadi
-
Publication number: 20070092868Abstract: A functional cassette for the detection of ligands comprises a first inner housing, a second middle housing and a third outer housing and each housing is at least partially rotatable relative to an adjoining housing. The first inner housing contains a central well adapted for receiving a sample, and the central well is in selectable fluid communication with at least one mixing chambers. The mixing chambers contain a reagent for forming a complex with a ligand. The first inner housing additionally comprises at least one compartments for the storage of a liquid crystalline material, and the compartments are in selectable fluid communication with at least one mixing chambers. The third outer housing comprises at least one detection chambers for observing the light transmission properties of a liquid crystal material and the detection chambers are in selectable fluid communication with the mixing.Type: ApplicationFiled: September 27, 2006Publication date: April 26, 2007Applicants: KENT STATE UNIVERSITY, NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINEInventors: Christopher Woolverton, Gary Niehaus
-
Patent number: 7186409Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.Type: GrantFiled: February 28, 2001Date of Patent: March 6, 2007Assignees: The Children's Medical Center Corporation, The General Hospital Corporation, Northeastern Ohio Universities College of MedicineInventors: Evan Y. Snyder, Xandra O. Breakefield, Karen S. Aboody, Ulrich Herrlinger, William P. Lynch
-
Publication number: 20070042489Abstract: The invention relates to self-contained assay cassette for detecting a ligand in a sample. The assay cassette provides for turbulent flow and mixing of the sample with assay components, including receptors that bind to a ligand, optional microspheres capable of binding the receptors or to which other secondary receptors are attached, and liquid crystalline materials. The assay cassette also provides for laminar flow of the mixed sample into a detection chamber where complexes between a receptor, ligand, and optional microspheres, is detected as transmission of polarized light through the detection chambers. The invention also relates to methods for detecting a ligand in a sample using turbulent flow to mix the sample with assay components, including liquid crystalline materials, and laminar flow of the mixed sample such that the liquid crystalline material assumes an ordered conformation in absence of a ligand.Type: ApplicationFiled: June 7, 2006Publication date: February 22, 2007Applicant: NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINEInventor: Gary Niehaus
-
Publication number: 20070031391Abstract: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by brain tumors. The invention also provides a method of preparing genetically engineered neural stem cells and a composition comprising genetically engineered neural stem cells in a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 12, 2006Publication date: February 8, 2007Applicants: Children's Medical Center Corporation, The General Hospital Corporation, Northeastern Ohio Universities College of MedicineInventors: Evan Snyder, Xandra Breakefield, Karen Aboody, Ulrich Herrlinger, William Lynch
-
Patent number: 7094809Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated tolan, particularly a polyhydroxylated tolan, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated tolan to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of treating a subject infected with Neisseria gonorrhea.Type: GrantFiled: June 11, 2003Date of Patent: August 22, 2006Assignees: Northeastern Ohio Universities College of Medicine, Kent State UniversityInventors: John Docherty, Chun-che Tsai
-
Patent number: 7060225Abstract: The invention relates to self-contained assay cassette for detecting a ligand in a sample. The assay cassette provides for turbulent flow and mixing of the sample with assay components, including receptors that bind to a ligand, optional microspheres capable of binding the receptors or to which other secondary receptors are attached, and liquid crystalline materials. The assay cassette also provides for laminar flow of the mixed sample into a detection chamber where complexes between a receptor, ligand, and optional microspheres, is detected as transmission of polarized light through the detection chambers. The invention also relates to methods for detecting a ligand in a sample using turbulent flow to mix the sample with assay components, including liquid crystalline materials, and laminar flow of the mixed sample such that the liquid crystalline material assumes an ordered conformation in absence of a ligand.Type: GrantFiled: March 22, 2004Date of Patent: June 13, 2006Assignee: Northeastern Ohio Universities College of MedicineInventor: Gary D. Niehaus
-
Patent number: 7038010Abstract: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80% identical, preferably at least 90% identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as “ADBP”, one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.Type: GrantFiled: November 9, 2001Date of Patent: May 2, 2006Assignees: Northeastern Ohio Universities College of Medicine, Temple UniversityInventors: Gary B. Schneider, Steven N. Popoff, Fayez Safadi
-
Patent number: 7037945Abstract: The present invention provides a method of inhibiting the formation of pseudorabies particles in a host cell. The method involves administering an effective amount of a poly-hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of reducing or inhibiting the growth of Neisseria gonorrhea and Neisseria meningiditis in vitro and in vivo. The method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene to a growth surface which has come into contact or could come into contact with the bacterium.Type: GrantFiled: December 11, 2001Date of Patent: May 2, 2006Assignee: Northeastern Ohio Universities College of MedicineInventor: John Docherty
-
Publication number: 20040185551Abstract: The invention relates to self-contained assay cassette for detecting a ligand in a sample. The assay cassette provides for turbulent flow and mixing of the sample with assay components, including receptors that bind to a ligand, optional microspheres capable of binding the receptors or to which other secondary receptors are attached, and liquid crystalline materials. The assay cassette also provides for laminar flow of the mixed sample into a detection chamber where complexes between a receptor, ligand, and optional microspheres, is detected as transmission of polarized light through the detection chambers. The invention also relates to methods for detecting a ligand in a sample using turbulent flow to mix the sample with assay components, including liquid crystalline materials, and laminar flow of the mixed sample such that the liquid crystalline material assumes an ordered conformation in absence of a ligand.Type: ApplicationFiled: March 22, 2004Publication date: September 23, 2004Applicant: Northeastern Ohio Universities College of MedicineInventor: Gary D. Niehaus
-
Patent number: 6599945Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated tolan, particularly a polyhydroxylated tolan, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated tolan to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of treating a subject infected with Neisseria gonorrhea.Type: GrantFiled: August 15, 2001Date of Patent: July 29, 2003Assignees: Northeastern Ohio Universities College of Medicine, Kent State UniversityInventors: John Docherty, Chun-che Tsai
-
Patent number: 6355692Abstract: The present invention provides a method of inhibiting the formation of pseudorabies particles in a host cell. The method involves administering an effective amount of a poly-hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of reducing or inhibiting the growth of Neisseria gonorrhea and Neisseria meningiditis in vitro and in vivo. The method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene to a growth surface which has come into contact or could come into contact with the bacterium.Type: GrantFiled: December 11, 2000Date of Patent: March 12, 2002Assignee: Northeastern Ohio Universities College of MedicineInventor: John Docherty
-
Patent number: 6197834Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated stilbene to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of reducing the cytopathic effect of HSV on mammalian cells.Type: GrantFiled: September 1, 1998Date of Patent: March 6, 2001Assignee: Northeastern Ohio Universities College of MedicineInventor: John Docherty
-
Patent number: 6153427Abstract: An erythropoietin-inducible, erythroid-specific DNA construct is disclosed. The DNA construct comprises a promoter sequence from a sheep juvenile beta globin gene, an erythroid-specific enhancer sequence from the locus control region of the human beta globin gene and a nucleotide coding sequence of interest.Type: GrantFiled: October 12, 1994Date of Patent: November 28, 2000Assignee: Northeastern Ohio Universities College of MedicineInventors: Donna King, Gary B. Schneider